Xolair 75 mg/0,5 ml & 150 mg/1,0 ml Powder and solvent for solution for injection
PDF Leaflet Revision Date: 08 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
For severe persistent allergic asthma, chronic spontaneous urticaria, and nasal polyps.
Dosage (summary)
75-600 mg subcutaneously every 2-4 weeks based on IgE levels and body weight.
Onset of Action / Duration
Onset: 4 weeks, Duration: Varies
Special Populations
- Elderly
- Children under 6 years
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and breastfeeding not established.
Key Drug Interactions
- Corticosteroids
- Beta agonists
- Antihistamines
Contraindications
- Hypersensitivity to omalizumab or excipients
Common side effects
- Headache
- Injection site reactions
- Fatigue
Counselling Points
- Monitor for signs of anaphylaxis
- Do not discontinue corticosteroids abruptly
- Store in refrigerator
Serious warnings
- Risk of anaphylaxis
- Not for acute asthma exacerbations
Important Disclaimer
The Xolair 75 mg/0,5 ml & 150 mg/1,0 ml Powder and solvent for solution for injection professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
